This patient cannot be considered as a control group, but he was screened for the trial, met the inclusion criteria, signed the informed consent, and was tested for HLA match with the study donor. ![]() Patient #10 did not receive the infusion because there was no HLA antigen sharing with the donor. One patient was diagnosed with human immunodeficiency virus (HIV) infection during admission (Patient #8). Included patients were like so many others admitted to hospital at that time, adult men (4) and women (6), median age 59 (IQR 46.5–66), median weight 80 kg (IQR 63.5–86), with moderate SARS-CoV-2 pneumonia with variable lymphopenia and mild hypertransaminasemia, with hypertension (3 patients), diabetes mellitus (1 patient), obesity (1 patient) or no comorbidities ( Table 1). The Lancet Regional Health – Western Pacificīetween September and November 2020, ten participants were enrolled in the trial, all but one received a single dose infusion of memory T cells ( Fig. 1).The Lancet Regional Health – Southeast Asia. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |